Healthcare Industry News: tyrosine kinase inhibitor
News Release - May 16, 2012
Epizyme Announces Appointment of Eric Hedrick, M.D., as Chief Medical OfficerCAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for patients with genetically-defined cancers, based on breakthroughs in the field of epigenetics, today announced that Dr. Eric Hedrick has joined the company as Chief Medical Officer.
Dr. Hedrick brings extensive experience in both the development and post-approval clinical management of innovative cancer therapies that target both hematologic malignancies and solid tumors. Eric was most recently at Pharmacyclics as VP of Oncology Development and Interim Chief Medical Officer, responsible for clinical development of the oncology portfolio, including the Bruton’s tyrosine kinase inhibitor, ibrutinib. Prior to Pharmacyclics, Eric held a number of positions in clinical development and medical affairs at Genentech, including oversight of multiple aspects of the development of Rituxan® (rituximab) and Avastin® (bevacizumab).
Robert Gould, Ph.D., CEO and President, said, “Epizyme is committed to the development of personalized therapeutics for patients with genetically-defined cancers. Dr. Hedrick brings a track record of success in developing innovative therapeutics for cancer patients. His appointment is another important step forward for Epizyme as we build a new leading biopharma company.”
“Epizyme’s personalized therapeutics represent potential breakthrough medicines for patients with genetically-defined cancers. I am excited to be joining the company as we advance our lead programs and pipeline,” said Eric Hedrick, M.D., Chief Medical Officer.
Epizyme is leading the discovery and development of small molecule histone methyltransferase (HMT) inhibitors, a new class of personalized therapeutics for patients with genetically-defined cancers, based on breakthroughs in the field of epigenetics. Genetic alterations in the HMTs are strongly associated with the underlying causes of multiple human diseases, including cancer. Epizyme’s patient-driven approach represents the future of personalized therapeutics by creating better medicines for the right patients more quickly and at lower cost than traditional approaches. Epizyme has benchmark partnerships with Celgene, GSK and Eisai and receives funding and strategic support from the Multiple Myeloma Research Foundation (MMRF) and the Leukemia & Lymphoma Society (LLS). www.epizyme.com
Rituxan® is a registered trademark of Genentech and Biogen Idec.
Avastin® is a registered trademark of Genentech.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.